BR112019002719A2 - acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em métodos relacionados a doenças de depósito lisossômico - Google Patents
acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em métodos relacionados a doenças de depósito lisossômicoInfo
- Publication number
- BR112019002719A2 BR112019002719A2 BR112019002719-0A BR112019002719A BR112019002719A2 BR 112019002719 A2 BR112019002719 A2 BR 112019002719A2 BR 112019002719 A BR112019002719 A BR 112019002719A BR 112019002719 A2 BR112019002719 A2 BR 112019002719A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methods related
- deposition diseases
- acetyl leucine
- Prior art date
Links
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title abstract 2
- 229960000669 acetylleucine Drugs 0.000 title abstract 2
- 230000008021 deposition Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002132 lysosomal effect Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente divulgação prevê o tratamento de doenças de depósito lisossômico (lsds) compreendendo a administração de acetil-leucina ou um sal farmaceuticamente aceitável da mesma.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1613828.1A GB201613828D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for lysosomal storage disorders |
GB1613828.1 | 2016-08-11 | ||
GB1702552.9 | 2017-02-16 | ||
GBGB1702552.9A GB201702552D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for lysosomal storage disorders |
GBGB1705762.1A GB201705762D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for lysosomal storage disorders |
GB1705762.1 | 2017-04-10 | ||
GBGB1706854.5A GB201706854D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for lysosomal storage disorders |
GB1706854.5 | 2017-04-28 | ||
PCT/IB2017/054928 WO2018029657A1 (en) | 2016-08-11 | 2017-08-11 | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019002719A2 true BR112019002719A2 (pt) | 2019-05-14 |
Family
ID=59859423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019002719-0A BR112019002719A2 (pt) | 2016-08-11 | 2017-08-11 | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em métodos relacionados a doenças de depósito lisossômico |
Country Status (28)
Country | Link |
---|---|
US (3) | US11400067B2 (pt) |
EP (4) | EP3865126A1 (pt) |
JP (3) | JP7393943B2 (pt) |
KR (3) | KR102412724B1 (pt) |
CN (1) | CN109843275A (pt) |
AU (2) | AU2017308864B2 (pt) |
BR (1) | BR112019002719A2 (pt) |
CA (1) | CA3033557A1 (pt) |
CY (2) | CY1121345T1 (pt) |
DK (2) | DK3482754T3 (pt) |
ES (2) | ES2716133T3 (pt) |
HK (1) | HK1253282B (pt) |
HR (2) | HRP20190344T1 (pt) |
HU (2) | HUE041914T2 (pt) |
IL (1) | IL264610A (pt) |
LT (2) | LT3359146T (pt) |
MA (2) | MA55947A (pt) |
MD (2) | MD3482754T2 (pt) |
ME (1) | ME03340B (pt) |
MX (2) | MX2019001577A (pt) |
PL (2) | PL3359146T3 (pt) |
PT (2) | PT3482754T (pt) |
RS (2) | RS61442B1 (pt) |
RU (2) | RU2749515C2 (pt) |
SG (1) | SG11201901048VA (pt) |
SI (2) | SI3359146T1 (pt) |
TN (1) | TN2019000032A1 (pt) |
WO (1) | WO2018029657A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7393943B2 (ja) * | 2016-08-11 | 2023-12-07 | イントラバイオ リミティド | リソソーム蓄積障害に関する医薬組成物及び使用 |
GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
MX2021006559A (es) * | 2018-12-06 | 2021-08-16 | Intrabio Ltd | Analogos deuterados de acetil-leucina. |
AU2020231189A1 (en) | 2019-03-02 | 2021-09-30 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
WO2020261230A1 (en) | 2019-06-28 | 2020-12-30 | Intrabio Ltd. | Combination therapy with acetyl-leucine and miglustat |
WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2749512B1 (fr) * | 1996-06-10 | 1999-08-13 | Pf Medicament | Utilisation de l'acetyl dl leucine pour le traitement des tremblements |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
WO2009114729A2 (en) * | 2008-03-14 | 2009-09-17 | Irm Llc | Compounds, compositions and methods for treating lysosomal storage diseases and disorders |
TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
GB201114017D0 (en) * | 2011-08-15 | 2011-09-28 | Univ Dundee | Inhibitors against endosomal/ysosomal enzymes |
WO2013182652A1 (en) * | 2012-06-06 | 2013-12-12 | Fondazione Telethon | Allosteric chaperones and uses thereof |
JP7393943B2 (ja) * | 2016-08-11 | 2023-12-07 | イントラバイオ リミティド | リソソーム蓄積障害に関する医薬組成物及び使用 |
SG11201901063SA (en) * | 2016-08-11 | 2019-03-28 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
-
2017
- 2017-08-11 JP JP2019507811A patent/JP7393943B2/ja active Active
- 2017-08-11 LT LTEP17767933.9T patent/LT3359146T/lt unknown
- 2017-08-11 US US16/324,301 patent/US11400067B2/en active Active
- 2017-08-11 SI SI201730032T patent/SI3359146T1/sl unknown
- 2017-08-11 HU HUE17767933A patent/HUE041914T2/hu unknown
- 2017-08-11 PT PT182107631T patent/PT3482754T/pt unknown
- 2017-08-11 CA CA3033557A patent/CA3033557A1/en active Pending
- 2017-08-11 MA MA055947A patent/MA55947A/fr unknown
- 2017-08-11 ES ES17767933T patent/ES2716133T3/es active Active
- 2017-08-11 WO PCT/IB2017/054928 patent/WO2018029657A1/en active Application Filing
- 2017-08-11 LT LTEP18210763.1T patent/LT3482754T/lt unknown
- 2017-08-11 DK DK18210763.1T patent/DK3482754T3/da active
- 2017-08-11 AU AU2017308864A patent/AU2017308864B2/en active Active
- 2017-08-11 MD MDE20190593T patent/MD3482754T2/ro unknown
- 2017-08-11 PL PL17767933T patent/PL3359146T3/pl unknown
- 2017-08-11 EP EP20215877.0A patent/EP3865126A1/en active Pending
- 2017-08-11 BR BR112019002719-0A patent/BR112019002719A2/pt active Search and Examination
- 2017-08-11 RS RS20210064A patent/RS61442B1/sr unknown
- 2017-08-11 PT PT17767933T patent/PT3359146T/pt unknown
- 2017-08-11 EP EP18210763.1A patent/EP3482754B1/en active Active
- 2017-08-11 CN CN201780062740.XA patent/CN109843275A/zh active Pending
- 2017-08-11 ME MEP-2019-60A patent/ME03340B/me unknown
- 2017-08-11 KR KR1020197007024A patent/KR102412724B1/ko active IP Right Grant
- 2017-08-11 MX MX2019001577A patent/MX2019001577A/es unknown
- 2017-08-11 DK DK17767933.9T patent/DK3359146T3/en active
- 2017-08-11 SI SI201730613T patent/SI3482754T1/sl unknown
- 2017-08-11 MD MDE20181131T patent/MD3359146T2/ro unknown
- 2017-08-11 RU RU2019106493A patent/RU2749515C2/ru active
- 2017-08-11 MA MA43876A patent/MA43876B1/fr unknown
- 2017-08-11 SG SG11201901048VA patent/SG11201901048VA/en unknown
- 2017-08-11 ES ES18210763T patent/ES2849566T3/es active Active
- 2017-08-11 RS RS20190334A patent/RS58478B1/sr unknown
- 2017-08-11 TN TNP/2019/000032A patent/TN2019000032A1/en unknown
- 2017-08-11 KR KR1020227039341A patent/KR20220154849A/ko not_active IP Right Cessation
- 2017-08-11 EP EP24154769.4A patent/EP4342461A3/en active Pending
- 2017-08-11 PL PL18210763T patent/PL3482754T3/pl unknown
- 2017-08-11 KR KR1020227009897A patent/KR102467953B1/ko active IP Right Grant
- 2017-08-11 EP EP17767933.9A patent/EP3359146B1/en active Active
- 2017-08-11 HU HUE18210763A patent/HUE052837T2/hu unknown
- 2017-08-11 RU RU2021115932A patent/RU2021115932A/ru unknown
-
2018
- 2018-10-02 HK HK18112571.2A patent/HK1253282B/zh unknown
-
2019
- 2019-02-03 IL IL264610A patent/IL264610A/en unknown
- 2019-02-07 MX MX2021008432A patent/MX2021008432A/es unknown
- 2019-02-21 HR HRP20190344TT patent/HRP20190344T1/hr unknown
- 2019-03-08 CY CY20191100279T patent/CY1121345T1/el unknown
-
2021
- 2021-01-12 CY CY20211100017T patent/CY1123844T1/el unknown
- 2021-01-29 HR HRP20210153TT patent/HRP20210153T1/hr unknown
-
2022
- 2022-01-07 JP JP2022001694A patent/JP2022050564A/ja active Pending
- 2022-06-30 US US17/854,027 patent/US20220331278A1/en active Pending
-
2023
- 2023-05-10 AU AU2023202903A patent/AU2023202903A1/en active Pending
-
2024
- 2024-02-02 US US18/430,858 patent/US20240197663A1/en active Pending
- 2024-02-27 JP JP2024027864A patent/JP2024059863A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019002719A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em métodos relacionados a doenças de depósito lisossômico | |
BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
BR112017008198A2 (pt) | pró-fármacos de carbidopa e l-dopa e métodos de uso | |
CL2016001756A1 (es) | Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular. | |
BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
BR112015030399B8 (pt) | Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3 | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
TW201613578A (en) | Pharmaceutical combinations | |
BR112016017620A2 (pt) | Composto esteroidal para uso no tratamento da encefalopatia hepática | |
BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
BR112019007145A2 (pt) | combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial | |
CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
BR112018071547A2 (pt) | acetil-leucina ou um sal farmaceuticamente aceitável desta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |